Back to top
more

Iterum Therapeutics (ITRM)

(Delayed Data from NSDQ)

$1.35 USD

1.35
75,400

-0.04 (-2.88%)

Updated May 24, 2024 03:59 PM ET

After-Market: $1.35 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ITRM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Iterum Therapeutics PLC [ITRM]

Reports for Purchase

Showing records 41 - 60 ( 69 total )

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 41

11/17/2020

Company Report

Pages: 7

3Q20 Recap; Sulopenem uUTI NDA Filing Imminent for 2H21 PDUFA

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 42

10/26/2020

Company Report

Pages: 2

Downward Spiral Continues with Offering

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 43

10/01/2020

Company Report

Pages: 2

NDA Filing in Q4

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 44

09/30/2020

Daily Note

Pages: 3

Regulatory Pathway Confirmed for Sulopenem in Subset of uUTI, but Near-Term Overhangs Remain

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 45

09/03/2020

Company Report

Pages: 2

Wrong Number on Rights - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 46

09/02/2020

Company Report

Pages: 2

Rights Buy a Little Time

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 47

08/10/2020

Company Report

Pages: 7

Awaiting FDA Meeting at End of 3Q20 to Elucidate Sulopenem''s U.S. Regulatory Path; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 48

07/15/2020

Company Report

Pages: 2

Wrong Time for Rights - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 49

06/30/2020

Company Report

Pages: 2

UUTI Halfway There, NDA Livin? on a Prayer

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 50

06/16/2020

Company Report

Pages: 6

Sulopenem Failed Phase 3 cUTI Trial; Downgrade to Neutral and Remove PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 51

06/04/2020

Company Report

Pages: 2

Bridge to Last Data Readout

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 52

06/02/2020

Company Report

Pages: 2

Beginning of the End?

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 53

05/15/2020

Company Report

Pages: 2

Q1 Results

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 54

05/15/2020

Company Report

Pages: 8

1Q20 Recap: Imminent Make or Break Readouts in UTI; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 55

03/13/2020

Company Report

Pages: 8

4Q Recap: Data Catalysts Imminent With Two Phase 3 Readouts; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 56

01/31/2020

Company Report

Pages: 6

Awaiting Pivotal UTI Data for Sulopenem in 1Q20; Affirm Buy, Reduce PT to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 57

01/21/2020

Company Report

Pages: 2

No Longer Worth the Risk - Sell

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 58

12/11/2019

Company Report

Pages: 2

One is the Loneliest Number

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 59

12/11/2019

Company Report

Pages: 8

Sulopenem Narrowly Misses in cIAI But We See Larger Value in UTI; Moderate PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Iterum Therapeutics PLC

Industry: Medical - Drugs

Record: 60

11/18/2019

Daily Note

Pages: 3

Top-line Results of SURE 2 in cUTI on Track for 1Q20; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party